Johnson & Johnson announces that the combination of Imbruvica (ibrutinib) and venetoclax is more effective than the combination of acalabrutinib and venetoclaxnétoclax, in the treatment of chronic lymphocytic leukemia (CLL) in first-line therapy, according to an indirect analysis (MAIC) presented at the EHA 2025 congress.
I+V reduces the risk of progression or death by 47% compared to A+V and achieves more responses with minimal residual disease (uMRD) three months after treatment.Final results from a Phase 2 study confirm the long-term clinical benefits of I+V, with progression-free survival and overall survival rates of 66% and 97% at 5.5 years.
Relapse occurred in 32% of patients, with no emergence of BTK or PLCG2 resistance mutations. No new safety signals were observed.Johnson & Johnson emphasizes that Imbruvica, validated by the longest follow-up in a fixed oral regimen, raises the standard of care for patients with CLL.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.